Logo

Health Canada Approves the Use of RINVOQ (upadacitinib) for the Treatment of Adults and Adolescents with Moderate to Severe Atopic Dermatitis

Share this
Health Canada Approves the Use of RINVOQ (upadacitinib) for the Treatment of Adults and Adolescents with Moderate to Severe Atopic Dermatitis

Health Canada Approves the Use of RINVOQ (upadacitinib) for the Treatment of Adults and Adolescents with Moderate to Severe Atopic Dermatitis

 

Share this article on WhatsApp, LinkedIn and Twitter



Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions